January 31, 2022 at 7:00 AM EST Enrollment in 48-week Phase 2 clinical trial expected to begin in Q1 2022…
Super UserFebruary 7, 2022
Intima Bioscience to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its solid tumor cell-therapy…
Super UserFebruary 7, 2022
POSITION DESCRIPTION – Entrepreneur-In-Residence EIRs will work in collaboration with SEED to mentor innovators and provide guidance to help them…
Super UserFebruary 7, 2022
These free 1:1 virtual sessions are an opportunity to discuss your company with experts in diagnostics, therapeutics, digital health and…
Super UserFebruary 7, 2022
These free 1:1 virtual sessions are an opportunity to discuss your company with experts in diagnostics, therapeutics, digital health and…
Super UserFebruary 1, 2022
- NVX-CoV2373 demonstrated overall efficacy of ~90% in PREVENT-19 clinical trial conducted during the emergence of variant strains GAITHERSBURG, Md.,…
Super UserFebruary 1, 2022
Board of Directors Elects New Chair, Vice-Chair, and Two New Members ROCKVILLE, MARYLAND, January 31, 2021 – The Board of…
Super UserFebruary 1, 2022
POSITION DESCRIPTION – Entrepreneur-In-Residence EIRs will work in collaboration with SEED to mentor innovators and provide guidance to help them…
Super UserJanuary 31, 2022
The current boom in life sciences development mirrors the tech industry, especially geographically; there is an incredible concentration of jobs…
Super UserJanuary 31, 2022